1: Home (ALT-H)
2: HMA Joint (ALT-M)
3: Human Medicines (ALT-U)
- 3.1: Heads of Agencies (ALT-E)
- 3.2: CMDh (ALT-C)
- 3.3: MRI Product Index (ALT-R)
- 3.4: Directory (ALT-I)
4: Veterinary Medicines (ALT-V)

You are here: Human Medicines > CMDh > Product Information > CMDh Recommendations

3.2.1: About CMDh (ALT-O)
3.2.2: Statistics (ALT-S)
3.2.3: Press Releases (ALT-P)
3.2.4: Procedural Guidance (ALT-L)
3.2.5: CMDh-Referrals
3.2.6: Product Information (ALT-T)
- 3.2.6.1: PhVWP Recommendations (ALT-W)
- 3.2.6.2: CMDh Recommendations (ALT-N)
- 3.2.6.3: Harmonisation of SmPCs - Article 30 Referrals (ALT-3)
- 3.2.6.4: Core SmPC/PL
3.2.7: Advice from CMDh
3.2.8: Templates
3.2.9: CMD Working Parties / Working Groups (ALT-K)
3.2.10: Paediatric Regulation (ALT-G)
3.2.11: Pharmacovigilance
3.2.12: Questions & Answers (ALT-Q)
3.2.13: Contact Form
3.2.14: Contact Points
3.2.15: What's new history (ALT-Y)

Azithromycin containing products in patients with severe hepatic impairment

CMDh Recommendations
Labelling & Package Leaflet warning (October 2010)

Gabapentin containing products

CMDh Recommendations
Labelling & Package Leaflet warning (July 2012)

Oxycodone containing medicinal products

CMDh Recommendations
Labelling & Package Leaflet warning - Taking alcohol (November 2008)